Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central nervous system, conolidine modulates alternate molecular targets. A Science Advances analyze found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid https://nazimr552ypi4.tkzblog.com/profile